Advertisement

Pharmaceutical Chemistry Journal

, Volume 45, Issue 2, pp 65–74 | Cite as

New group of class III antiarrhythmic drugs: piperid-4-ylethane derivatives

  • R. G. Glushkov
  • S. D. Yuzhakov
  • A. I. L’vov
  • G. P. Zhikhareva
  • N. K. Davydova
  • O. S. Sizova
  • V. V. Asnina
  • E. N. Salin
Search for New Drugs

A series of new piperid-4-ylethane derivatives possessing antiarrhythmic activity has been synthesized and studied. The most active compound, 1-(4-fluorophenyl)-1-(4-nitrobenzoylamino)-2-(N-ethylpiperid-4-yl)ethane (niferidyl) hydrochloride, was selected for clinical trials as a potential class III antiarrhythmic drug.

Key words

piperid-4-ylethane derivatives synthesis class III antiarrhythmic activity 1-(4-fluorophenyl)-1-(4-nitrobenzoylamino)-2-(N-ethylpiperid-4-yl)ethane hydrochloride pharmacological study 

References

  1. 1.
    Bays de Luna, P. Coumel, and J. F. Zeclerc, Am Heart J., 117, 151–159 (1989).CrossRefGoogle Scholar
  2. 2.
    J. A. Butera, W. Spinelli, V. Anantharaman, et al., J. Med. Chem., 34, 3212–3228 (1991).PubMedCrossRefGoogle Scholar
  3. 3.
    S. T. Coplen, E. M. Antman, and J. A. Berlin, Circulation, 82, 1106–1116 (1990).PubMedCrossRefGoogle Scholar
  4. 4.
    R. H. Falk, Ann. Intern. Med., 111, 107–111 (1989).PubMedGoogle Scholar
  5. 5.
    J. Morganroth and J. E. Goin, Circulation, 84, 1977–1983 (1991).PubMedGoogle Scholar
  6. 6.
    The Cardiac Arrhythmia Suppression Trial (CAST) investigators, N. Engl. J. Med., 321, 406–412 (1989).CrossRefGoogle Scholar
  7. 7.
    A. J. Camm and D. Catritsis, Eur. Heart J., 13, f44-f52 (1992).Google Scholar
  8. 8.
    R. C. Klein, Eur. Heart J., 14(H), 78–84 (1993).PubMedGoogle Scholar
  9. 9.
    The CASCADE investigators, Am. J. Cardiol., 72, 280–287 (1993).CrossRefGoogle Scholar
  10. 10.
    T. R. Vrobel, P. E. Miller, N. D. Mostow, et al., Prog. Cardiovasc. Dis., 31, 393–426 (1989).PubMedCrossRefGoogle Scholar
  11. 11.
    D. Catritsis and A. J. Camm, Eur. Heart J., 14, H93-H99 (1993).Google Scholar
  12. 12.
    Drugs Future, 24, 682–683 (1999).Google Scholar
  13. 13.
    M. D. Mashkovskii, R. G. Glushkov, E. V. Dorodnikova, et al., Khim.-farm. Zh., 29(3), 27–31 (1995).Google Scholar
  14. 14.
    R. G. Glushkov, S. P. Golitsin, E. V. Dorodnikova, et al., Vestn. Ross. Akad. Med. Nauk, No. 11, 38–42 (1998).Google Scholar
  15. 15.
    R. G. Glushkov,M. D. Mashkovski, and S. D. Yuzhakov, Drugs Future, 22, 30–33 (1997).Google Scholar
  16. 16.
    R. A. Marinchak, K. M. O’Connor, et al., J. Cardiovasc. Pharmacol., 14, 389–395 (1989).PubMedCrossRefGoogle Scholar
  17. 17.
    L. Carlson, O. Almgren, and G. Duker, J. Cardiovasc. Pharmacol., 16, 276–285 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2011

Authors and Affiliations

  • R. G. Glushkov
    • 1
  • S. D. Yuzhakov
    • 1
  • A. I. L’vov
    • 2
  • G. P. Zhikhareva
    • 2
  • N. K. Davydova
    • 2
  • O. S. Sizova
    • 2
  • V. V. Asnina
    • 2
  • E. N. Salin
    • 2
  1. 1.MirFarm CompanyObninskRussia
  2. 2.Center for Drug ChemistryAll-Russia Research Institute of Pharmaceutical ChemistryMoscowRussia

Personalised recommendations